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Abstract
Nanoparticle-based delivery has become an important strategy to advance siRNA and antisense
oligonucleotides into clinical reality. However, limited biodistribution of nanoparticles and the
toxicity of some nanocarriers restrict the wider application of this strategy. To address these issues
we aimed to construct oligonucleotide delivery systems which are non-cytotoxic and smaller than
typical nanoparticles. Thus, a morpholino oligonucleotide was conjugated to a tumor-targeting
RGD peptide, and then, multiple RGD-oligo conjugates were linked to a single molecule of
human serum albumin via a reductively responsive linkage. The resultant nanoconjugates showed
uniform and monodispersed size distribution with a diameter of 13 nm. A single nanoconjugate
molecule contains 15 oligonucleotides as well as 15 targeting ligands on the surface of albumin.
The nanoparticle demonstrated 61-fold enhancement in receptor-specific cellular delivery of
oligonucleotides in integrin-expressing tumor cells compared to the non-targeted control
nanoconjugates and were able to robustly enhance functional activity of the oligonucleotide at low
nanomolar concentrations without causing cytotoxicity. Due to their small size, the targeted
nanoconjugates could penetrate deeply and distribute throughout 3-D tumor spheroids, whereas
the conventional nanoparticles with sizes over 300 nm could only deliver to the cells on the
surface of the tumor spheroids. As a result of their greater cellular delivery, smaller size, and lack
of cytotoxicity compared to conventional nanoparticles, the multivalent nanoconjugates may
provide an effective tool for targeting oligonucleotides to tumors and other diseased tissues.
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INTRODUCTION
Antisense and siRNA oligonucleotides promise to become a new generation of anti-tumor
agents, as they enjoy high specificity by recognizing their targets based on base pairing, and
are capable of manipulating many desirable targets that are “undruggable” by small
molecules.[1] New types of therapeutic oligonucleotides, such as microRNA antagonists and
splice-switching oligonucleotides (SSOs), provide additional tools to modulate the
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expression and function of tumor related genes.[2-4] For example, SSOs can modulate
alternative splicing by hybridizing to pre-mRNA sequences and blocking access of various
splicing factors.[2] Thus, an SSO can redirect Bcl-x splicing from anti-apoptotic Bcl-xL to
pro-apoptotic Bcl-xS and thereby induce apoptosis of cancer cells.[5] By eliminating an
over-expressed cancer-permissive splice variant and inducing an apoptotic splice variant
simultaneously, SSOs can potentially achieve greater pharmacological effect than small
molecule inhibitors that only act on a single function.[2, 6] Despite their enormous potential,
pharmacological targets within the cells are poorly accessible to oligonucleotides since they
are hydrophilic and often charged macromolecules.[7] Utilization of nanoparticles as
delivery vehicle holds promise for unleashing the tremendous potential of therapeutic
oligonucleotides for tumor therapy. Yet, for ultimate translation of oligonucleotides into
clinical reality, the current delivery systems need to be optimized to confront the challenges
posed by the highly heterogeneous and dynamic nature of tumors.[8]
The size of nanoparticles must be optimized in order for them to overcome the delivery
barriers in vivo, as particle size has a substantial impact on the biodistribution of
nanoparticles, especially to tumor sites.[9] Particles larger than 7 nm (the size of albumin)
typically have low renal filtration; however, those larger than 300 nm tend to be cleared
quickly by the reticuloendothelial system.[10] Thus, nanoparticles with a size between 7 and
300 nm can remain in the circulation for a long time, which is a prerequisite for targeted
tumor delivery. On the other hand, larger particles may take advantage of the enhanced
permeability and retention (EPR) effect in tumor sites.[11] From studies with xenograft
tumor models in mice, nanoparticles with a size around 400 nm tend to maximally exploit
the EPR effect.[12] However, the validity of this rule for drug delivery to human tumors is
controversial since xenograft tumor models are fundamentally different from spontaneous
human tumors.[13] Tumors are highly heterogeneous in terms of vascular leakage.[14]
Larger particles may have better distribution in leaky sites of tumors; however, poor
delivery to less leaky sites will lead to incomplete eradication of the tumor, resulting in
tumor relapse. Further, most solid tumors develop high interstitial fluid pressure which
reduces convection of the nanoparticles from the circulation to tumor tissues.[15, 16] Thus,
nanoparticle delivery to tumors, largely through diffusion, favors smaller particles.[14]
Taken together, we consider smaller nanoparticles (7-50 nm) a superior system for
delivering oligonucleotides to tumors.
Targeted delivery is another way to overcome the biological barriers limiting
oligonucleotide-based therapeutics.[7] To achieve active targeting, a ligand on the delivery
system binds to its receptor on the surface of diseased cells and then undergoes receptor-
mediated endocytosis, so as to overcome the cell membrane barrier for intracellular delivery
of oligonucleotides.[17] In addition, the therapeutic significance of tumor targeting lies in
the ability to accumulate a drug specifically to cancer cells and thereby to enhance
therapeutic activity and minimize drug-related toxicity. To achieve tumor targeting in vivo,
multivalent display of the targeting moiety is often required to achieve effective binding to
the target cells in a physiological environment, where the endogenous ligands compete for
binding to the target and the shear stress in the circulation drag the delivery system away
from the tumor site.[18] For example, polymer-based nanoparticles coated with multiple
transferrin ligands were able to deliver siRNAs to solid tumors overexpressing transferrin
receptors and cause gene specific RNAi activity in humans;[19] this clinical study highlights
the advantage of using nanoparticles to construct multivalent targeting systems.
Taken together, ideal tumor targeting nanoparticles should be versatile enough to display
multivalent targeting ligands and carry sufficient payload. Yet, equally important is that they
are small enough to penetrate all tumor tissues with diverse vascular leakage. It is a
tremendous challenge to construct versatile but small nanoparticles for oligonucleotide
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delivery. Currently, nanoparticles of oligonucleotides are often prepared by complexation of
cationic lipids and polymers with negatively charged oligonucleotides. This method often
leads to heterogeneous and polydisperse structures that are typically larger than 100 nm.
Thus, the resultant nanoparticles have not successfully translated oligonucleotide-based
therapy into clinical reality due to disadvantages such as incomplete delivery, low
reproducibility, and considerable systemic toxicity[20]. In this study, we aim to use
chemical conjugation methods to construct polycationic-free nanoparticles that combine
broad biodistribution and multivalent tumor targeting for oligonucleotide delivery.
Materials and Methods
Preparation of Albumin-based Nanoconjugates
The overall strategy was to covalently conjugate SSOs to the RGD peptide that was
selective for integrin αvβ3, a cell surface glycoprotein that is preferentially expressed in
angiogenic endothelia and in some tumors,[21] and then link multiple RGD-SSO conjugates
to a molecule of albumin as a carrier protein. The SSO (5′-
GTTATTCTTTAGAATGGTGC-3′) was custom synthesized by Gene Tools, LLC
(Philomath, OR, USA). This oligonucleotide was phosphorodiamidate morpholino oligomer
(PMO) functionalized with a primary amine at the 5′ position and a disulfide amide for
sulfhydryl linkage at the 3′ position, and was referred to as NH2-PMO-S-S-R. RGD peptide
was conjugated to the amine group at the 5′end of the PMO according to a method described
previously.[22] Briefly, a maleimide group was introduced to the PMO by reacting it with
N-[γ-maleimidobutyryloxy] succinimide ester (GMBS, Thermo Fisher Scientific, Rockford,
IL, USA) at a 3:1 molar ratio of GMBS to PMO in phosphate buffered saline (PBS, pH 7.2)
for 30 min at room temperature, and this was followed by gel filtration in an illustra NAP-25
Column (GE Healthcare, Uppsala, Sweden). The thiol group on cyclic RGDfK needed for
conjugation was freshly generated by incubation of cyclo[RGDfK(Ac-SCH2CO)] (Peptide
International, Louisville, KY, USA) in the Deacetylation Solution (50 mM Hydroxylamine,
5 mM EDTA in PBS, pH 7.0) at room temperature for 1 h. The maleimide group on the
PMO was then reacted with the thiol group of cyclic RGDfK at a 1:3 molar ratio of
maleimide to thiol in PBS with 5 mM EDTA (pH 7.0) for 1 h at room temperature, and the
resultant peptide-PMO conjugates were purified by gel filtration in an illustra NAP-25
Column (GE Healthcare).
Human serum albumin (HSA) was labeled with a fluorescent dye at Cys-34 by reacting it
with Alexa Fluor® 633 C5 Maleimide (Life Technologies, Carlsbad, CA, USA) at a 1:3
molar ratio of protein to dye in PBS supplemented with 1 mM EDTA (pH 7.0) for 2 h at
room temperature. The labeled HSA was purified by gel filtration in a PD-10 Desalting
Column (GE Healthcare). The amino groups of the albumin were then reacted with the
bifunctional crosslinker N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP, Thermo
Fisher Scientific) at a 1:25 molar ratio of protein to linker in PBS with 1 mM EDTA (pH
7.5) for 1 h at room temperature. The excess amount of SPDP was removed by gel filtration
in a PD-10 Column. The average number of 2-pyridyldithio group (the sulfhydryl-reactive
portion of SPDP) linked to albumin was determined as 18 by observing the release of
pyridine-2-thione (λmax = 343 nm) from the intermediate HSA-SPDP conjugates after being
treated with excess amount of DTT (Sigma-Aldrich, St. Louis, MO, USA).
The thiol group on the RGD-PMO conjugates needed for conjugation with the 2-
pyridyldithio group on albumin was freshly generated by treating the disulfide bond of the
RGD-PMO-S-S-R conjugates with 10 mM DTT for 1 h at room temperature, and any
residual amount of DTT was removed by gel filtration in an illustra NAP-25 Column. The 2-
pyridyldithio groups on the albumin derivative were then reacted with the thiol group of
RGD-PMO conjugates at a 1:20 molar ratio of protein to conjugate in PBS with 1 mM
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EDTA (pH 7.0) overnight at room temperature, and the final product was purified by gel
filtration using a column with Sephadex G-100 gel (GE Healthcare) to remove the excess
amount of the RGD-PMO conjugates and other byproducts.
In order to prepare control nanoconjugates without the RGD peptides, the PMO with the
same sequence but only functionalized with disulfide amide at the 3′ position was custom
synthesized by Gene Tools, LLC. After treatment with DTT, the PMO with a thiol group
was reacted with the SPDP modified albumin in the same conditions as that for preparation
of the RGD targeted nanoconjugates.
Physical Characterization of Nanoconjugates
The final products were first analyzed using size-exclusion chromatography. Samples (100
μL) containing the nanoconjugates or albumin were injected into a Varian HPLC system
(ProStar/Dynamax, Walnut Creek, CA, USA) equipped with a Yarra SEC-3000 column
(Phenomenex, Torrance, CA, USA). The nanoconjugates containing PMOs were detected by
OD260, while the albumin was detected by OD280. Gel Filtration Markers Kit for Protein
Molecular Weights 29,000-700,000 Da (Sigma) was used as the size standards.
The average particle sizes of the nanoconjugates in PBS were determined using a Zetasizer
Nano (Malvern Instruments, Westborough, MA, USA) at a fixed angle of 90° and a
temperature of 25°C. Light scattering intensity was maintained within the required range of
the instrument (5 × 104 to 1 × 106 counts/sec) in all the measurements. Each sample was
analyzed in triplicate.
The size of the nanoconjugates was confirmed with Transmission Electron Microscopy
(TEM). In this experiment, the targeted nanoconjugates were diluted and dropped on 200
mesh carbon-coated copper grids (Ted Pella, Redding CA) and allowed to attach for 2 min.
Uranyl acetate aqueous solution (4%) was then added on the grid for 2 min to counterstain
the nanoparticles. Samples were viewed using a LEO EM910 transmission electron
microscope operating at 80kV (LEO Electron Microscopy, Oberkochen, Germany). Digital
images were acquired using a Gatan Orius SC1000 CCD Digital Camera and Digital
Micrograph 3.11.0 (Gatan, Pleasanton, CA, USA).
Serum Stability and Release of PMO by Sulfhydryls
The HSA-(PMO-RGD)15 nanoconjugates containing 1 μM PMO were incubated in PBS
containing 20% serum at 37 °C for 16 h or in PBS containing 10 mM glutathione and 100
μM cysteine at at 37°C for 4 h, using PBS as a control. After incubation, samples were
eluted in a column with Sephadex G-100 gel. The PMO contents in the fractions were then
detected by OD260, while the albumin was detected by Alexa Fluor 633 fluorescence.
Cells
Integrin αvβ3 expressing A375SM cells were stably transfected with a reporter gene
comprised of the firefly luciferase coding sequence interrupted by an aberrant intron, as
described previously,[23] and were referred to as A375/Luc705 cells. They were cultured in
DMEM medium (Life Technologies, Grand Island, NY, USA) containing 10% FBS (Sigma)
and 200 μg/mL hygromycin B (Roche, Mannheim, Germany). M21+ melanoma cells with
high expression of integrin αvβ3, as well as M21− cells that lack this integrin, were obtained
from Dr. D. Cheresh (University of California, San Diego, CA, USA)[24] and were cultured
in DMEM medium supplemented with 10% FBS.
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Total cellular uptake of the Alexa Fluor® 633-labeled nanoconjugates was measured by
flow cytometry using a LSR II cell analyzer (Becton-Dickenson, San Jose, CA, USA). After
treatment with the nanoconjugates for 4 h, the cells were trypsinized and were analyzed by
flow cytometry, with a 639 nm laser coupled with a 675/20 emission filter for Alexa Fluor®
633.
Oligonucleotide Treatment of Cells and Luciferase Assay
A375/Luc705 cells were seeded on 24-well plates at 5 × 104 cells per well. On the following
day, the nanoconjugates in 500 μl of Opti-MEM I medium (Life Technologies) were then
added to each well. Following the 4-h treatment at 37 °C, FBS was added to each well to the
concentration of 1% (v/v). After 16 h, cells were washed with PBS and incubated in DMEM
supplemented with 1% FBS for 48 h prior to harvest. Activation of luciferase gene
expression due to correction of splicing by the SSO was determined using a Luciferase assay
kit (Promega, Madison, WI, USA) on a FLUOstar Omega microplate reader (BMG
LABTECH, Cary, NC, USA). Protein content was determined by the BCA protein assay
(Thermo Fisher Scientific) with bovine serum albumin as a standard. Background luciferase
expression was determined by measuring luciferase activity in the cells without the
oligonucleotide treatment, and these values were then subtracted from the results in the
treated cells to obtain response values to represent the increase of luciferase expression by
the nanoconjugates of the SSO.
Confocal Fluorescence Microscopy
Live cell confocal microscopy was performed to examine the subcellular distribution of the
targeted nanoconjugates. The A375/Luc705 cells were transfected with baculovirus
expression vectors for GFP chimeras of Rab5, Rab7, or lysosome-associated membrane
glycoprotein 1 (LAMP-1) (Organelle Lights™, Life Technologies). The day following
transfection cells were incubated with the Alexa Fluor® 633-labeled nanoconjugates (50 nM
equivalent PMOs) in Opti-MEM media for 4 h. Cells were imaged on a Zeiss 510 meta
confocal microscope using 488 nm and 633 nm laser lines.
Tumor Spheroid Study
Tumor spheroids were grown using A375/GFP cells to study nanoconjugate uptake and
penetration in three-dimensional (3-D) culture according to a method described previously.
[25] Briefly, two thousand of the cells in 30 μL of cell suspension were seeded to each well
of a sterilized Nunc Microwell™ MiniTrays (Fisher Scientific, Pittsburgh, PA, USA). The
tray was then inverted and placed on an orbital shaker in CO2 incubator and left undisturbed
for 7 days; at this point the spheroids were approximately 400 μm in diameter. After
washing with PBS, the spheroids were placed in a 1.5% agarose-coated 48 well plate with
200 μL OptiMEM media and were treated with nanoparticles for 4 h. Spheroids were
harvested and fixed in 4% paraformaldehyde before being mounted on a slide with
fluoromount G (Electron Microscopy Sciences, Hatfield, PA, USA). Images were taken on a
Zeiss 510 meta confocal microscope.
Cytotoxicity Assay
The cytotoxicity of nanoconjugates was measured with the Alamar Blue assay. In brief,
A375/Luc705 cells were seeded in 96-well plates at 3000 cells/well. After 24 hours, the cells
were exposed to different concentrations of nanoconjugates for 24 h. Dose-containing
medium was replaced with fresh medium, and cells were incubated for another 48 h. Alamar
Blue reagent (Life Technologies) was added and incubated for 2 hour. The samples were
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read in a FLUOstar Omega microplate reader (BMG LABTECH, Cary, NC, USA) set at 540
nm excitation wavelength and 590 nm emission wavelength.
Data Analysis
Data are expressed as mean ± SD from three measurements unless otherwise noted.
Statistical significance was evaluated using t-test for two-sample comparison or ANOVA
followed by Dunnet’s test for multiple comparisons. The data were analyzed with GraphPad
Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
RESULTS
Synthesis and Characterization of Nanoconjugates
The overall strategy for preparation of the nanoconjugates is outlined in Fig 1. First, the
single sulfhydryl group on HSA was labeled with the far red fluorophore Alexa Fluor® 633.
Subsequently, approximately 18 surface amino groups were reacted with the bifunctional
reagent SPDP, which was determined by release of the colored product pyridine-2-thione
(λmax = 343 nm) from the modified albumin by DTT treatment. After introducing a
maleimide group to the 5′-end of PMO using a bi-functional linker GMBS, excess thiol-
containing cyclic RGD peptide was reacted with the terminal maleimide groups to form
RGD-PMO conjugates. After generation of free thiol groups at the 3′-end of PMOs, they
were linked to the SPDP-conjugated albumin to form RGD nanoconjugates. To prepare
control nanoconjugates without RGD ligands, PMOs containing only a disulfide bond at 3′-
end were treated with DTT and were then reacted with the SPDP modified albumin. The
number of PMOs linked to the albumin was determined in two ways. First, formation of the
colored product pyridine-2-thione was monitored as the 3′-thiol PMO reacted with the
SPDP-conjugated albumin. Second, the concentrations of PMO and HSA in the purified
final product were determined using OD260 and Alexa Fluor® 633 fluorescence,
respectively, and then were used to calculate the ratio of PMO to HSA in the final product.
Both of these methods led to close agreement with 15-16 oligonucleotides linked per
albumin in various preparations. The targeted and control nanoconjugates were then termed
HSA-(PMO-RGD)15 and HSA-PMO15, respectively.
The SEC-HPLC behaviors of the starting materials and the final nanoconjugates are
illustrated in Fig 2A. Alexa Fluor® 633-modified HSA eluted earlier than the RGD-PMO
direct conjugates in the column with the retention time of 8.6 and 10.9 min, respectively.
When the RGD-PMO conjugates were further linked to the albumin, the final
nanoconjugates eluted even earlier than the albumin itself with the retention time of 7.8 min.
The minor peak in front of the HSA chromatography peak represents aggregates of albumin
proteins. Correspondingly, there was a small front peak in the chromatography for the
targeted nanoconjugates, which may result from conjugation of the RGD-PMO conjugates
to the albumin aggregates. Thus, the final products of the nanoconjugates are as
homogenous as albumin and linking multiple RGD-PMO does not cause aggregation of
albumin.
The molecular size of the resultant nanoconjugates was estimated using dynamic light
scattering and transmission electron microscopy. Average particle sizes for the starting
material albumin and the nanoconjugates measured by dynamic light scattering are
summarized in Table 1 and a representative size distribution graph is shown in Fig S1. The
diameters for albumin, the control, and targeted nanoconjugates were 7.14, 12.74, and 12.95
nm, respectively. There was no statistical difference between the sizes of the targeted and
control nanoconjugates. Polydispersity index values were small (about 0.3), indicating
uniform and monodispersed nanoparticles. The targeted nanoconjugates were visualized by
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TEM which revealed a diameter averaging 10 nm, consistent with their hydrodynamic size
(Fig 2B). The nanoconjugates are stable for at least 3 months when stored in buffer at room
temperature, with no indication of aggregation or loss of biological activity.
Serum Stability and Release of PMO by Sulfhydryls
We first tested the serum stability of the targeted nanoconjugates by incubation in PBS or
PBS with 20% serum at 37 °C for up to 16 h. The incubated samples were eluted in a
column with Sephadex G-100 gel, which separates the nanoconjugates and albumin from the
RGD-PMO conjugates. For both PBS and serum treated samples, the PMO contents
(measured by OD260) overlapped the albumin contents (measured by Alexa Fluor® 633
fluorescence) (Fig 3), indicating the RGD-PMO conjugates were not cleaved by PBS or
serum treatment and the targeted nanoconjugates were stable in serum for at least 16 h.
Then, we tested whether intracellular sulfhydryls can release the PMOs from the
nanoconjugates using PBS containing 10 mM L-glutathione and 100 μM cysteine, the typical
free thiol concentrations in the cytosol.[26] In gel filtration of the treated sample using a
Sephadex G-100 column, over 78% of PMO contents eluted slower and were separated from
the nanoconjugates or albumin contents when incubated in the sulfhydryl solution for 4 h
(Fig 3), indicating that the majority of the RGD-PMO conjugates were released from the
nanoconjugates by the sulfhydryls. We tested cellular uptake of the treated samples in A375/
Luc705 cells. Consistent with the gel filtration result, the targeted nanoconjugates after PBS
or serum treatment maintained their receptor-selective uptake, whereas cellular uptake of the
sample treated by the sulfhydryls was dramatically reduced (Fig S2), suggesting that the
RGD-PMO conjugates was released from the Alexa Fluor® 633 labeled albumin by
sulfhydryls.
Cellular Uptake of Nanoconjugates
The total cellular uptake of targeted and control nanoconjugates was evaluated by incubating
cells with these molecules for 4 h and then measuring total cell-associated fluorescence by
flow cytometry. As seen in Fig 4A, there was 61-fold greater uptake of the targeted
nanoconjugate as compared to the control nanoconjugates. Co-incubation with excess
amounts (10 μM) of a cyclic RGD peptide (RGDfV), a selective inhibitor of integrin αvβ3,
led to inhibition of the uptake of the targeted nanoconjugates, but did not affect that of the
control nanoconjugates. Moreover, uptake of the targeted nanoconjugates was 18-fold
higher in integrin αvβ3-expressing M21+ cells than that in M21− cells that lack this integrin
(Fig 4B). These observations support the concept that the cellular uptake of the RGD
nanoconjugates depends on the integrin αvβ3 receptor-mediated endocytosis. Cell uptake of
the nanoconjugates was evaluated as a function of concentration. The uptake of the HSA-
(PMO-RGD)15 nanoconjugates as a function of concentration was well described by a
classic saturable michaelis-menten model, whereas that for the control conjugates showed
linear uptake (Fig 4C). These data are consistent with a saturable, receptor-mediated
endocytosis accounting for uptake of the targeted nanoconjugate in A375/Luc705 cells.
By controlling the ratio of the SDPD modified albumin and RGD-PMO-SH conjugates in
the final conjugation reaction, we prepared nanoconjugates that contain 5 or 10 RGD-PMO
conjugates per albumin molecule, and they were termed as HSA-(PMO-RGD)5 and HSA-
(PMO-RGD)10. The same amounts of the three nanoconjugates (3.3 nM of albumin) were
dosed to A375/Luc705 cells and total cellular uptake of the nanoconjugates was measured
by flow cytometry. As shown in Fig 4D, the uptake was proportional to the number of RGD
ligands displayed on the surface of the nanoconjugates. The uptake for the HSA-(PMO-
RGD)15 nanoconjugates were 3- and 1.6-folded higher than that for HSA-(PMO-RGD)5 and
HSA-(PMO-RGD)10, respectively.
Ming et al. Page 7













Intracellular Trafficking of Nanoconjugates
We examined the subcellular distribution of the nanoconjugates. As seen in Fig 5A, live
cells treated with the targeted nanoconjugates displayed substantial intracellular
fluorescence at 4 h, where cells treated with the control nanoconjugates exhibited little
intracellular fluorescence. To further understand the cellular uptake and trafficking of the
targeted nanoconjugates, we utilized chimeras of GFP with marker proteins for specific
endomembrane compartments to visualize the subcellular distribution of the targeted
nanoconjugates in live cells. As seen in Fig 5B, there was considerable co-localization of the
fluorescent nanoconjugates with Rab7 and LAMP-1, markers for late endosome and
lysosome, respectively, indicating that the RGD targeted nanoconjugates were transported to
late endosomes and lysosomes. In contrast, at this point in the uptake process, there was
little co-localization of fluorescent nanoconjugate with Rab5, the early endosome marker.
Functional Activity of Nanoconjugates
In order to evaluate the pharmacological effectiveness of the conjugates, A375/Luc705 cells
were incubated with PMOs, the RGD-PMO conjugates, the control HSA-PMO15
nanoconjugates, and targeted HSA-(PMO-RGD)15 nanoconjugates, all containing 50 nM
PMOs, and the increase in luciferase activity was quantitated using the luciferase activity
assay. As indicated in Fig 6A, treatment with the HSA-(PMO-RGD)15 nanoconjugates
produced a significant increase in luciferase expression compared to PMO (14.1-fold), the
RGD-PMO conjugates (11.0-fold), and the control nanoconjugates (16.2-fold) at the same
concentration. As shown Fig 6B, co-incubation with 10 μM RGDfV peptide led to full
inhibition of the effect of the HSA-(PMO-RGD)15 nanoconjugates on luciferase induction.
In contrast, RGDfV did not affect the luciferase induction by the control HSA-PMO15
nanoconjugates. This observation supports the concept that the effect of the targeted
nanoconjugates on splicing largely depends on its initial uptake via integrin αvβ3. As shown
in Fig 6C, the luciferase induction by the targeted nanoconjugates as a function of
concentration was also saturable and well described by a general sigmoid model. These data
suggests that saturable, receptor-mediated endocytosis is the main contributor to the
effectiveness of the targeted nanoconjugates.
To further enhance functional delivery of SSOs by the targeted nanoconjugates, we applied
a small molecule called Retro-1 that promotes release of oligonucleotides from late
endosomes,[27] where the targeted nanoconjugates traffic (Fig 5B). After treating the A375/
Luc705 cells with targeted nanoconjugates, we further treated them with Retro1 at different
doses. Dramatic enhancement of luciferase induction was observed with increasing doses of
Retro-1 and the induction level with 50 μM Retro-1 treatment was superior to the
Lipofectamine formulation of phosphorothioate (PS) SSO in the same sequence and at the
same concentration (Fig 6D).
Uptake of Nanoconjugates in Tumor Spheroids
We investigated tumor penetration of the targeted nanoconjugates using tumor spheroids of
A375/GFP cells. For comparison, we included two conventional nanoparticles for
oligonucleotide delivery prepared by complexation methods, Lipofectamine 2000 complexes
of negatively charged PS SSO and PEI polyplexes of RGD-PS oligo conjugates. They have
particle sizes of 870 and 336 nm, respectively, and showed potent cellular delivery into the
tumor cells in 2-D culture.[28, 29] There was no obvious difference in morphology of the
spheroids after 4h treatment with the targeted nanoconjugates and the two control
nanoparticles, as compared to untreated control spheroids. Confocal imaging was carried out
in order to visualize the site of localization of the nanoparticles in the spheroid. As shown in
Fig 7, the lipoplexes and polyplexes could only deliver oligonucleotides to the cells on the
surface of spheroids. In contrast, the targeted nanoconjugates were homogeneously
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distributed throughout the spheroid, within the observable depth of the confocal microscope
(~75 μm), suggesting that small nanoparticles can penetrate deeply into the spheroid. To
confirm the superior penetration of the nanoconjugates in tumor spheroid, we digested the
tumor spheroids into single cells and measured cellular uptake of the nanoparticles using
flow cytometry. As shown in Fig S3, the cells from the spheroids treated with the targeted
nanoconjugates showed a homogenous increase in cellular uptake, while the cells from
spheroids treated with the lipoplexes or polyplexes showed less than 10% of cells with
increased cellular uptake, confirming the result obtained from confocal microscopy.
Toxicity
There was little toxicity associated with the use of the nanoconjugates at the concentrations
examined. Thus in the Alamar Blue assay, the viability of the cells treated with up to 800
nM equivalent oligonucleotides in nanoconjugates were over 90% of the control cells (Fig
8). In the dose-response and time-response studies, the cells treated by the nanoconjugates
showed similar total protein amounts as compared to the untreated control cells in BCA
assay (data not shown). In addition, the cells treated with the nanoconjugates maintained
normal morphology as illustrated in the confocal images of Fig 5.
Discussion
To overcome the various inherited disadvantages of conventional delivery systems for
therapeutic oligonucleotides, we aimed to construct monomolecular nanoconjugates that are
small, highly specific, and non-cytotoxic. Thus, albumin, neutral morpholino oligomers, and
RGD peptides are selected as the carrier, therapeutic entity, and targeting moiety,
respectively, because all of them have demonstrated superior safety profiles in clinical
applications. Further, we utilize the morpholino oligomers as not only cargo molecules but
also building blocks to display targeting ligands on nanoparticles, and thereby we are able to
prepare nanoparticles that are 13 nm in diameter but versatile in displaying multivalent
targeting ligands and carrying high payloads.
The resultant nanoconjugates showed uniform and monodispersed size distribution with a
diameter of 13 nm, and thus they are large enough to avoid quick renal filtration but small
enough to penetrate through the vasculatures in tumor sites. These smaller nanoconjugates
are especially advantageous over conventional nanoparticles (typically larger than 100 nm)
due to their ability to deliver to less leaky tumor sites, where relatively tight vasculatures
and high interstitial fluid pressure prevent effective tumor penetration by the larger
nanoparticles. Recently, polyplexes of 6 nm hydrodynamic diameter has been constructed
for siRNA delivery.[30] However, only one molecule of siRNA duplex was loaded in this
delivery system.[30] In contrast, a single molecule of our nanoconjugates contains 15
oligonucleotides. Thus the loading efficiency of oligonucleotides was estimated to be over
60%, which provides another advantage over the conventional nanoparticles prepared by
complexation.
Ideally, oligonucleotide delivery systems should be stable in blood so that they can circulate
long enough to allow targeted delivery in tumor sites. On the other hand, to produce
pharmacological actions, the therapeutic oligonucleotides must release from the delivery
system in the target cells so that they can cross nuclear membrane and bind their target pre-
mRNA in the nucleus.[7, 31] We utilized a reductively responsive linkage disulfide bond to
link PMOs to albumin so that cellular glutathione can potentially break the linkage and
release the PMOs in the target cells. The stability study using cell-free assays revealed that
the targeted nanoconjugates are stable in serum while the majority of the oligonucleotides
can be released from the nanoconjugates by glutathione at the intracellular level. When the
nanoconjugates are delivered into the cells, intracellular glutathione could potentially break
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the disulfide bond and release the PMOs. The kinetics of PMO release in the cells will be
examined by using more sensitive assay to quantify cellular PMO level in future studies.
The nanoparticle demonstrated 61-fold enhancement in receptor-specific uptake of
oligonucleotides in tumor cells compared to the non-targeted control nanoconjugates. This
dramatically increased uptake is due to display of multivalent targeting ligands on the
surface of the nanoconjugates as the uptake level was proportional to the number of RGD
ligands displayed on the surface of the nanoconjugates (Fig 4D). In addition, the targeted
nanoconjugates produced 11-fold higher functional activity of SSO compared to the
monomeric RGD-PMO conjugates when the same amount of PMOs were used (Fig 6A).
These observations support the notion that displaying multivalent targeting peptides on the
surface of a nanoparticle can dramatically enhance binding affinity of the ligands to the
receptors.[32] Further, these data indicate that the enhanced receptor binding can lead to
superior receptor-mediated cellular uptake and functional delivery of oligonucleotides.
Initial uptake of the nanoconjugates is followed by sequential intracellular trafficking into a
variety of endomembrane compartments. In this study, we observed that the RGD-targeted
nanoconjugates were partially transported to late endosomes and lysosomes, but not to early
endosomes (Fig 5B). In addition, functional delivery of the targeted nanoconjugates was
dramatically increased by Retro-1 (Fig 6D), which has been shown to promote the release of
oligonucleotides from late endosomes.[27] Thus, these results support the notion that the
targeted nanoconjugates escape from late endosomes in the cells. Because the fluorescent
dye was linked to albumin instead of PMO, it is still unknown where the PMOs are released
from the albumin carrier. Thus, additional studies are warranted to reveal precise trafficking
pathways of the nanoconjugates.
The targeted nanoconjugates can robustly enhance functional activity of the oligonucleotide
at low nanomolar concentrations, indicating that the enhancement in cellular uptake by
multivalent targeting leads to an increase in pharmacological activity of the
oligonucleotides. A PMO, capable of inducing exon skipping in dystrophin pre-mRNA in
the nucleus, has shown to restore dystrophin function in patients with Duchenne muscular
dystrophy in a phase II clinical trial.[33] However, without using any delivery system, a
high dosage (> 2 mg/kg bodyweight) of this PMO was required to demonstrate its functional
activity in the patients.[33] Consistent with this clinical observation, over 1 μM PMO was
needed to induce reporter gene expression in a cellular model.[34] In this study, the targeted
nanoconjugates produced a 14-fold higher induction than free PMO at the same PMO
concentration, indicating that the targeted nanoconjugates may produce therapeutic effects at
a lower dose.
For complete eradication of solid tumors, anticancer drugs, including therapeutic
oligonucleotides, must penetrate tumors efficiently and reach all cancer cells in a therapeutic
concentration.[35] Tumor spheroids resemble micrometastasis or intervascular regions of
large solid tumors and have an in vivo-like differentiation pattern due to cell-matrix and
cell-cell interactions, and therefore have been used to study tumor penetration of anticancer
drugs.[25, 36] It has been reported recently that tumor penetration and cellular uptake of
ultrasmall gold nanoparticles were similar in tumor spheroids and tumor xenograft in mice,
indicating tumor spheroid is a good model to examine nanoparticle penetration behavior.
[37] In this study, the targeted nanoconjugates could penetrate deeply and distribute
throughout 3-D tumor spheroids, whereas the conventional nanoparticles with sizes over 300
nm could only deliver to the cells on the surface of the tumor spheroids (Fig 7). This result
supports the notion that smaller nanoparticles show superior penetration behavior into tumor
spheroids than larger nanoparticles.[38] However, there are more biological barriers
preventing drug delivery to tumor in vivo compared to tumor spheroid model. For example,
interstitial fluid pressure of solid tumors is higher than that in tumors spheroids due to lack
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of blood vessels in spheroids. Therefore, further development of the nanoconjugate delivery
system will entail substantial in vivo experimentation.
In spite of substantial uptake of the targeted nanoconjugates in the cells, little cytotoxicity
was observed with the use of the nanoconjugates in various experiments in this study. As
substantial toxicity was observed in application of cationic delivery systems for therapeutic
oligonucleotides [20], we avoided using cationic carriers in this delivery system. Instead,
albumin was selected because of its long history as a biodegradable and nontoxic carrier for
drug delivery.[39] In addition, the PMOs are neutral oligonucleotides and have been well
tolerated with no drug-related side effects when given to patients with Duchenne muscular
dystrophy [33]. Utilization of targeted delivery can lower the oligonucleotide dose that is
required for desired pharmacological outcomes, and thus can further reduce the possibility
of toxicity caused by the therapeutic oligonucleotides.
CONCLUSIONS
In the current study, we successfully prepared monomolecular nanoconjugates that are
small, highly specific, and non-cytotoxic. The resultant nanoconjugates with a diameter of
13 nm may have improved half-life in circulation and a broader tissue distribution profile
compared to conventional nanoparticles for oligonucleotide delivery. In spite of their small
size, the loading efficiency (over 60%) of our nanoconjugates is greater than many
nanoparticles currently used for drug/gene delivery. By utilizing oligonucleotides as not
only cargo molecules but also building blocks for the display of targeting ligands on
nanoparticles, we are able to prepare nanoparticles that are 13 nm in diameter but versatile
in displaying multivalent targeting ligands and carrying high payloads. Thus, the targeted
nanoconjugates demonstrated dramatic increases in receptor-specific cellular uptake, tumor
penetration, and functional activity of therapeutic oligonucleotides in cancer cells. Due to
the superior cellular delivery and smaller size compared to typical nanoparticles, multivalent
nanoconjugates may provide an effective tool for targeting oligonucleotides to tumors and
other diseased tissues.
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Refer to Web version on PubMed Central for supplementary material.
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Preparation of HSA-(PMO-RGD)15 nanoconjugates a
a. Alexa 633-Mal = Alexa Fluor 633 C5 maleimde; RGD-SH = cyclo[RGDfK-COCH2SH];
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Characterization of Nanoconjugates. A. SEC-HPLC chromatography of RGD-PMO
conjugates, HSA, and HSA-(PMO-RGD)15 nanoconjugates. B. TEM image of HSA-(PMO-
RGD)15 nanoconjugates. The sample is counterstained by uranyl acetate. The average
particle size is estimated to be 10 nm.
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Serum stability and release of PMO by sulfhydryls. The HSA-(PMO-RGD)15
nanoconjugates containing 1 μM PMO were incubated in PBS containing 20% serum at 37
°C for 16 h or in PBS containing 10 mM glutathione and 100 μM cysteine at at 37°C for 4 h,
using PBS as a control. After incubation, samples were eluted in a column with Sephadex
G-100 gel. The PMO contents in the fractions were then detected by OD260, while the
albumin was detected by Alexa Fluor 633 fluorescence.
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Cellular uptake of nanoconjugates. A. A375/Luc705 cells were treated with HSA-PMO15
and HSA-(PMO-RGD)15 (both contain 50 nM PMO) in the absence or presence of excess
free RGD peptide (RGDfV, 10 μM) for 4 hours and total cellular uptake of the Alexa 633-
labeled nanoconjugates was measured by flow cytometry. B. Uptake of HSA-(PMO-RGD)15
(50 nM PMO) was compared in αvβ3 positive M21+ cells and M21− cells that do not
express this integrin. C. A375/Luc705 cells were treated with increasing concentrations of
HSA-PMO15 and HSA-(PMO-RGD)15 for 4 hours followed by measurement of total
cellular uptake by flow cytometry. D. Uptake of the RGD targeted nanoconjugates of
different ratios of RGD-PMO to albumin (5, 10, and 15) and containing 3.3 nM HSA was
compared in A375/Luc705 cells. Data represent mean ± S.D. of a representative experiment
in triplicate. Statistical significance was evaluated using t-test for two-sample comparison or
ANOVA followed by Dunnet’s test for multiple comparisons. *** indicates p < 0.001.
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Subcellular localization of the nanoconjugates. A. A375/Luc705 cells were treated with with
HSA-PMO15 and HSA-(PMO-RGD)15 for 4 h, and then were observed by confocal
microscopy. B. A375/Luc705 cells were transfected with GFP chimeras that serve as
markers for several endomembrane compartments (Rab 5, early endosomes; Rab 7, late
endosomes; Lamp1, lysosome). Thereafter, cells were incubated with 50 nM Alexa 633
labeled targeted nanoconjugates for 4 h. Live cells were observed by confocal microscopy.
Green image, GFP fluorescence. Red image, Alexa 633 fluorescence.
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Functional delivery of SSOs by the nanoconjugates. A. Comparison of luciferase induction
by the treatments of PMO, RGD-PMO, HSA-PMO15, and HSA-(PMO-RGD)15 (all contain
50 nM PMO). B. The luciferase induction by HSA-PMO15 and HSA-(PMO-RGD)15 (both
contain 50 nM PMO) in the absence or presence of excess free RGD peptide. C. In the dose-
dependence experiment, A375/Luc705 cells were treated with increasing concentrations of
the HSA-PMO15 and HSA-(PMO-RGD)15 for 16 h followed by another 48-h culture. D.
Retro-1 enhances functional delivery by the targeted nanoconjugates. After treatment with
the targeted nanoconjugates, A375/Luc705 cells were treated by various amounts of Retro-1.
The luciferase activity was measured after 24-h culture. The blue bar represents the
luciferase induction by Lipofectamine 2000 complexes of negatively charged PS
oligonucleotide in the same sequence and at the same concentration.
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Penetration of the nanoconjugates in tumor spheroids. Tumor spheroids of A375/GFP cells
were treated with the RGD targeted nanoconjugates, the lipoplexes and polyplexes of PS
SSO (all contain 100 nM SSOs) for 4h. After fixation, the spheroids were observed by
confocal microscopy. Green image: GFP fluorescence. Red image: Alexa 633 fluorescence
for the nanoconjugates or TAMRA fluorescence for the other nanoparticles.
Ming et al. Page 20














Cytotoxicity of the Nanoconjugates. The cytotoxicity of the HSA-PMO15 and HSA-(PMO-
RGD)15 nanoconjugates to A375/Luc705 cells was measured in 96-well plates with the
Alamar Blue assay.
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Table 1
Particle sizes of the nanoconjugates 
a
Particle Size (nm) P.I.
HSA 7.14 ± 0.03 0.34 ± 0.01
HSA-PMO 12.74 ± 0.52 0.37 ± 0.03
HSA-PMO-RGD 12.95 ± 0.14 0.31 ± 0.03
a
Results are expressed as mean ± SD (n = 3)
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